

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Xilio Therapeutics, Inc.

(Name of Issuer)

Common stock, par value \$0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☒ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

- Names of Reporting Persons
- 1 StemPoint Capital LP
- Check the appropriate box if a member of a Group (see instructions)
- 2 ☐ (a)
- ☐ (b)
- 3 Sec Use Only
- Citizenship or Place of Organization
- 4 DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	0.00	
		Shared Voting Power
	6	
	628,866.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	628,866.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
	628,866.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	
11	Percent of class represented by amount in row (9)	
	9.5 %	
12	Type of Reporting Person (See Instructions)	
	IA, PN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons	
	StemPoint Capital Management GP LLC	
	Check the appropriate box if a member of a Group (see instructions)	
2	☐ (a)	
	☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization	
	DELAWARE	
		Sole Voting Power
	5	
	0.00	
Number of Shares Beneficially Owned by Each Reporting Person With:		Shared Voting Power
	6	
	628,866.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	628,866.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person	
	628,866.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	
	☐	

11	Percent of class represented by amount in row (9)
	9.5 %
	Type of Reporting Person (See Instructions)
12	OO

Comment for Type of Reporting Person: StemPoint Capital Management GP LLC is a limited liability company.

SCHEDULE 13G

CUSIP No.

	Names of Reporting Persons
1	Michelle Ross
	Check the appropriate box if a member of a Group (see instructions)
2	☐ (a)
	☐ (b)
3	Sec Use Only
	Citizenship or Place of Organization
4	UNITED STATES
	Sole Voting Power
5	0.00
Number of	Shared Voting Power
Shares	6
Beneficially	628,866.00
Owned by	Sole Dispositive Power
Each	7
Reporting	0.00
Person	Shared Dispositive
With:	Power
	8
	628,866.00
	Aggregate Amount Beneficially Owned by Each Reporting Person
9	628,866.00
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
10	☐
	Percent of class represented by amount in row (9)
11	9.5 %
	Type of Reporting Person (See Instructions)
12	HC, IN

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Xilio Therapeutics, Inc.

(b) Address of issuer's principal executive offices:

Item 2.

Name of person filing:

- (a) This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person").
- Address or principal business office or, if none, residence:
- (b) The business addresses of each Reporting Person is: 520 Madison Avenue, 19th Floor New York, NY 10022
- Citizenship:
- (c) StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware. StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware. Michelle Ross is a citizen of the United States of America.
- Title of class of securities:
- (d) Common stock, par value \$0.0001 per share
- (e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) ☒ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) ☒ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- (a) Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 628,866 shares of Common Stock, par value \$0.0001 per share (the "Common Stock"), consisting of (i) 343,154 shares of Common Stock through the exercise of a pre-funded warrant (the "Pre-Funded Warrants"), (ii) 142,856 shares of Common Stock underlying Series A Warrants, and (iii) 142,856 shares of Common Stock underlying Series C Warrants. The Pre-Funded Warrants, Series A Warrants, and Series C Warrants are subject to a beneficial ownership limitation of 9.99% (the "Beneficial Ownership Limitation").

Percent of class:

- (b) Each Reporting Person may be deemed to beneficially own 9.5% shares of Common Stock, which is calculated based on (i) 5,982,839 shares of Common Stock reported as issued and outstanding as of May 8, 2026 in the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 12, 2026, plus 343,154 shares of Common Stock which may be acquired upon the exercise of the Pre-Funded Warrants, 142,856 shares of Common Stock which may be acquired upon the exercise of Series A Warrants, and 142,856 shares of Common Stock which may be acquired upon the exercise of Series C Warrants, which are subject to the Beneficial Ownership Limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act. %

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or to direct the vote:

628,866. Comment: Shared voting power includes 628,866 Warrants beneficially owned by the Reporting Persons.

(iii) Sole power to dispose or to direct the disposition of:

(iv) Shared power to dispose or to direct the disposition of:

628,866. Comment: Shared dispositive power includes 628,866 Warrants beneficially owned by the Reporting Persons.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

StemPoint Capital LP

Signature: /s/ Sean C. Tan

Name/Title: Sean C. Tan, Authorized Signatory

Date: 08/14/2026

StemPoint Capital Management GP LLC

Signature: /s/ Sean C. Tan

Name/Title: Sean C. Tan, Authorized Signatory

Date: 08/14/2026

Michelle Ross

Signature: /s/ Michelle Ross

Name/Title: Michelle Ross

Date: 08/14/2026

Exhibit Information

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

JOINT FILING AGREEMENT

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

August 14, 2026

STEMPOINT CAPITAL LP

BY: STEMPOINT CAPITAL MANAGEMENT GP LLC
ITS GENERAL PARTNER

BY: /S/ SEAN C. TAN
NAME: SEAN C. TAN
TITLE: AUTHORIZED SIGNATORY

STEMPOINT CAPITAL MANAGEMENT GP LLC

BY: /S/ SEAN C. TAN
NAME: SEAN C. TAN
TITLE: AUTHORIZED SIGNATORY

MICHELLE ROSS
/S/ MICHELLE ROSS
